VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up

Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The pain drug will be marketed by the name of Journavx.Following the nod, Journavx has become the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years.Per the company, Journavx has the potential to ...